Related Experiment Video

Updated: Aug 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Aromatase inhibitors: future directions

C Kent Osborne1, Rachel Schiff

  • 1Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA. kosborne@breastcenter.tmc.edu

The Journal of Steroid Biochemistry and Molecular Biology
|July 16, 2005
PubMed

Insights

Aromatase inhibitors are effective endocrine therapy for postmenopausal breast cancer by blocking estrogen production. Further research is needed on long-term toxicity and optimal duration for breast cancer treatment.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Estrogen and estrogen receptors are crucial in breast cancer development and progression.
  • Aromatase inhibitors effectively reduce estrogen levels in postmenopausal women.
  • These inhibitors are a primary endocrine therapy for metastatic breast cancer.

Purpose of the Study:

  • To review the role of aromatase inhibitors in breast cancer therapy.
  • To explore the mechanisms underlying aromatase inhibitor effectiveness.
  • To identify strategies for overcoming resistance to endocrine therapies.

Main Methods:

  • Review of experimental studies and clinical observations on estrogen receptor activity.
  • Analysis of aromatase inhibitor efficacy in postmenopausal breast cancer.
  • Investigation of estrogen receptor signaling pathways and crosstalk with growth factors.

Main Results:

  • Aromatase inhibitors are the leading endocrine therapy for metastatic breast cancer in postmenopausal women.
  • These agents are likely to become standard adjuvant therapy.
  • Blocking both genomic and non-genomic estrogen receptor activities is vital for optimal endocrine therapy effectiveness.

Conclusions:

  • Aromatase inhibitors demonstrate excellent performance in breast cancer treatment.
  • Understanding estrogen receptor signaling and its crosstalk with growth factors explains their efficacy.
  • Targeting growth factor receptors may prevent or delay resistance to aromatase inhibitors and other endocrine therapies.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...